Ken Griffin Galera Therapeutics, Inc. Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.09 - $0.27 $53,104 - $159,314	590,052 New	590,052 $82,000
Q2 2023 Aug 14, 2023	BUY	$2.5 - $3.42 $85,492 - $116,953	34,197 New	34,197 $106,000
Q4 2022 Feb 14, 2023	SELL	$1.34 - $1.78 $21,397 - $28,423	-15,968 Reduced 98.25%	284 $0
Q3 2022 Nov 14, 2022	BUY	$1.15 - $2.1 $370 - $676	322 Added 2.02%	16,252 $28,000

909K

Ticker GRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,821,600
Market Cap $1.07M
Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical tria...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.